Long-Term Pertuzumab Outcomes in HER2+ Breast Cancer: Insights from APHINITY 8-Year Data and NeoSphere Pooled Analysis
Dr. Tarantino discuss long-term safety and efficacy findings from the APHINITY trial's 8-year follow-up with pertuzumab, and insights from the NeoSphere study's impact on treatment strategies based on efficacy and safety data.
Video content above is prompted by the following:
- Please provide some background on APHINITY 8-Year follow up data evaluating pertuzumab with adjuvant trastuzumab and chemotherapy in early HER2+ breast cancer.
- With a median follow up of 8.4 years, what are your impressions of the long-term safety and efficacy profile of pertuzumab?
- Is the IDFS benefit observed with pertuzumab sustained over the extended follow-up period?
- Does the addition of pertuzumab have a positive impact on quality of life for patients with HER2-positive early breast cancer, beyond just extending IDFS?
- Please review the rationale and study design for the NeoSphere pooled analysis study and discuss implications of these data on treatment landscape.
- Which treatment combinations were investigated and how did efficacy outcomes vary between the treatment arms? What are your impressions of these data?
- How did tumor size, node involvement, or biomarker positivity affect efficacy outcomes?
- What are your impressions of the safety data?
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
